Last $53.12 USD
Change Today -0.65 / -1.21%
Volume 70.3K
CBPO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

china biologic products inc (CBPO) Snapshot

Open
$52.97
Previous Close
$53.77
Day High
$53.60
Day Low
$52.79
52 Week High
08/27/14 - $58.00
52 Week Low
09/3/13 - $23.50
Market Cap
1.3B
Average Volume 10 Days
55.8K
EPS TTM
$2.34
Shares Outstanding
24.5M
EX-Date
--
P/E TM
22.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for CHINA BIOLOGIC PRODUCTS INC (CBPO)

Related News

No related news articles were found.

china biologic products inc (CBPO) Related Businessweek News

No Related Businessweek News Found

china biologic products inc (CBPO) Details

China Biologic Products, Inc., a biopharmaceutical company, is engaged in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers. It offers human albumin for the treatment of shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also offers human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human albumin and human immunoglobulin for intravenous injection (IVIG) products for original immunoglobulin deficiency, secondary immunoglobulin deficiency, and auto-immune deficiency diseases; and Thymopolypeptides injection for the treatment of original and secondary T-cell deficiency syndromes, auto-immune deficiency diseases, and a range of cell immunity deficiency diseases, as well as assists in the treatment for tumors. In addition, it provides human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; human tetanus immunoglobulin for the prevention and therapy of tetanus; placenta polypeptide that is used for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative heating; and Human coagulation factor VIII for the treatment of coagulopathie, such as hemophilia A. The company’s products under development comprise human prothrombin complex concentrate; human hepatitis B immunoglobulin (PH4) for intravenous injection; human fibrinogen; Varicella hyperimmune globulins; immune globulin intravenous, Caprylate/Chromatography virus filtration; and human antithrombin III. It distributes its products directly or through distributors. The company is headquartered in Beijing, the People's Republic of China.

1,467 Employees
Last Reported Date: 03/12/14

china biologic products inc (CBPO) Top Compensated Officers

Executive Chairman, Chief Executive Officer a...
Total Annual Compensation: $878.7K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $328.7K
Corporate Vice President
Total Annual Compensation: $265.5K
Senior Corporate Vice President and Corporate...
Total Annual Compensation: $244.2K
Corporate Vice President
Total Annual Compensation: $169.3K
Compensation as of Fiscal Year 2013.

china biologic products inc (CBPO) Key Developments

China Biologic Products, Inc. Announces Resignation of Charles (Le) Zhang as Director

On August 4, 2014, Mr. Charles (Le) Zhang resigned from the board of directors of China Biologic Products, Inc., effective from the same date. Mr. Zhang's resignation was due to personal reasons and not because of any disagreement with the company on any matter relating to the company's operations, policies or practices.

China Biologic Products, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Period Ended June 30, 2014; Reiterates Earnings Guidance for the Full Year of 2014

China Biologic Products, Inc. announced unaudited consolidated earnings results for the second quarter and six months period ended June 30, 2014. For the quarter, the company reported total sales of $60,073,984 against $53,580,523 a year ago. Income from operations was $28,873,235 against $25,315,313 a year ago. Earnings before income taxes expense was $31,257,818 against $26,723,328 a year ago. Net income was $26,771,661 or $0.79 diluted per share against $22,977,679 or $0.57 diluted per share a year ago. Net income attributable to company was $19,724,955 against $16,161,926 a year ago. Adjusted net income attributable to the company was $20,522,830 or $0.82 diluted per share against $17,406,925 or $0.62 diluted per share a year ago. For the six months, the company reported total sales of $116,340,561 against $107,612,255 a year ago. Income from operations was $56,851,968 against $51,293,705 a year ago. Earnings before income taxes expense was $60,548,585 against $53,242,556 a year ago. Net income was $50,724,210 or $1.47 diluted per share against $44,890,005 or $1.11 diluted per share a year ago. Net income attributable to company was $37,998,626 against $31,077,786 a year ago. Net cash provided by operating activities was $39,027,261 against $37,908,728 a year ago. Payment for property, plant and equipment was $10,243,198 against $11,912,603 a year ago. Adjusted net income attributable to the company was $39,594,376 or $1.53 diluted per share against $33,801,545 or $1.21 diluted per share a year ago. For the full year of 2014, the company reiterates its full year financial forecast of total sales in the range of $230 million to $240 million and full year non-GAAP adjusted net income in the range of $67 million to $69 million.

China Biologic Products, Inc. to Report Q2, 2014 Results on Aug 05, 2014

China Biologic Products, Inc. announced that they will report Q2, 2014 results After-Market on Aug 05, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBPO:US $53.12 USD -0.65

CBPO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hualan Biological Engineering Inc CNY26.51 CNY +0.25
Jiangxi Boya Bio-Pharmaceutical Co Ltd CNY48.70 CNY +0.86
Shanghai RAAS Blood Products Co Ltd CNY63.30 CNY 0.00
View Industry Companies
 

Industry Analysis

CBPO

Industry Average

Valuation CBPO Industry Range
Price/Earnings 23.3x
Price/Sales 6.0x
Price/Book 6.1x
Price/Cash Flow 21.4x
TEV/Sales 4.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHINA BIOLOGIC PRODUCTS INC, please visit www.chinabiologic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.